{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:29:45Z","timestamp":1771928985289,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01172-y","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:47:03Z","timestamp":1771926423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient"],"prefix":"10.1007","volume":"49","author":[{"given":"Xinyu","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yarong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinfang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"17","key":"1172_CR1","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","volume":"47","author":"G Gatta","year":"2011","unstructured":"G. Gatta, J.M. van der Zwan, P.G. Casali, S. Siesling, A.P. Dei Tos, I. Kunkler, R. Otter, L. Licitra, S. Mallone, A. Tavilla, A. Trama, R. Capocaccia, R.w. group, rare cancers are not so rare: the rare cancer burden in Europe. Eur. J. Cancer. 47(17), 2493\u20132511 (2011)","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"1172_CR2","first-page":"261","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"C.E. DeSantis, J.L. Kramer, A. Jemal, The burden of rare cancers in the United States. CA Cancer J. Clin. 67(4), 261\u2013272 (2017)","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"1172_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S1470-2045(05)70471-X","volume":"7","author":"G Gatta","year":"2006","unstructured":"G. Gatta, L. Ciccolallo, I. Kunkler, R. Capocaccia, F. Berrino, M.P. Coleman, R. De Angelis, J. Faivre, J.M. Lutz, C. Martinez, T. Moller, R. Sankila, E.W. Group, Survival from rare cancer in adults: a population-based study. Lancet Oncol. 7(2), 132\u2013140 (2006)","journal-title":"Lancet Oncol."},{"issue":"8","key":"1172_CR4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"G. Gatta, R. Capocaccia, L. Botta, S. Mallone, R. De Angelis, E. Ardanaz, H. Comber, N. Dimitrova, M.K. Leinonen, S. Siesling, J.M. van der Zwan, L. Van Eycken, O. Visser, M.P. Zakelj, L.A. Anderson, F. Bella, I. Kaire, R. Otter, C.A. Stiller, A. Trama, R.A.w. group, burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 18(8), 1022\u20131039 (2017)","journal-title":"Lancet Oncol."},{"issue":"2","key":"1172_CR5","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S1470-2045(15)00388-5","volume":"17","author":"JY Blay","year":"2016","unstructured":"J.Y. Blay, J.M. Coindre, F. Ducimetiere, I. Ray-Coquard, The value of research collaborations and consortia in rare cancers. Lancet Oncol. 17(2), e62\u2013e9 (2016)","journal-title":"Lancet Oncol."},{"issue":"2","key":"1172_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1470-2045(15)00485-4","volume":"17","author":"KM Komatsubara","year":"2016","unstructured":"K.M. Komatsubara, R.D. Carvajal, The promise and challenges of rare cancer research. Lancet Oncol. 17(2), 136\u2013138 (2016)","journal-title":"Lancet Oncol."},{"issue":"1","key":"1172_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejso.2018.03.030","volume":"45","author":"AM Frezza","year":"2019","unstructured":"A.M. Frezza, A. Trama, J.Y. Blay, P.G. Casali, Networking in rare cancers: what was done, what\u2019s next. Eur. J. Surg. Oncol. 45(1), 16\u201318 (2019)","journal-title":"Eur. J. Surg. Oncol."},{"key":"1172_CR8","doi-asserted-by":"crossref","unstructured":"J. Lu, Y. Li, J. Wang, S. Cell (Neuroendocrine) Carcinoma of the Cervix (eds.), An Analysis for 19 Cases and Literature Review. Front Cell Infect Microbiol. 12916506 (2022)","DOI":"10.3389\/fcimb.2022.916506"},{"issue":"13","key":"1172_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"C. Le Tourneau, J.P. Delord, A. Goncalves, C. Gavoille, C. Dubot, N. Isambert, M. Campone, O. Tredan, M.A. Massiani, C. Mauborgne, S. Armanet, N. Servant, I. Bieche, V. Bernard, D. Gentien, P. Jezequel, V. Attignon, S. Boyault, A. Vincent-Salomon, V. Servois, M.P. Sablin, M. Kamal, X. Paoletti, investigators, molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16(13), 1324\u20131334 (2015)","journal-title":"Lancet Oncol."},{"issue":"8","key":"1172_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","volume":"4","author":"J Marquart","year":"2018","unstructured":"J. Marquart, E.Y. Chen, V. Prasad, Estimation of the percentage of US patients with cancer who benefit from Genome-Driven oncology. JAMA Oncol. 4(8), 1093\u20131098 (2018)","journal-title":"JAMA Oncol."},{"issue":"11","key":"1172_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrclinonc.2012.160","volume":"9","author":"J Munoz","year":"2012","unstructured":"J. Munoz, R. Kurzrock, Targeted therapy in rare cancers\u2013adopting the orphans. Nat. Rev. Clin. Oncol. 9(11), 631\u2013642 (2012)","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"1172_CR12","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S1470-2045(15)00386-1","volume":"17","author":"N Boyd","year":"2016","unstructured":"N. Boyd, J.E. Dancey, C.B. Gilks, D.G. Huntsman, Rare cancers: a sea of opportunity. Lancet Oncol. 17(2), e52\u2013e61 (2016)","journal-title":"Lancet Oncol."},{"issue":"3","key":"1172_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/cas.14669","volume":"112","author":"T Kondo","year":"2021","unstructured":"T. Kondo, Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. Cancer Sci. 112(3), 953\u2013961 (2021)","journal-title":"Cancer Sci."},{"issue":"1","key":"1172_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12943-023-01720-2","volume":"22","author":"S Vivekanandhan","year":"2023","unstructured":"S. Vivekanandhan, D. Bahr, A. Kothari, M.A. Ashary, M. Baksh, E. Gabriel, Immunotherapies in rare cancers. Mol. Cancer. 22(1), 23 (2023)","journal-title":"Mol. Cancer"},{"issue":"7","key":"1172_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"J. Drost, H. Clevers, Organoids in cancer research. Nat. Rev. Cancer. 18(7), 407\u2013418 (2018)","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"1172_CR16","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ccell.2021.07.020","volume":"39","author":"V Veninga","year":"2021","unstructured":"V. Veninga, E.E. Voest, Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 39(9), 1190\u20131201 (2021)","journal-title":"Cancer Cell."},{"key":"1172_CR17","doi-asserted-by":"crossref","unstructured":"J.T. Neal, X. Li, J. Zhu, V. Giangarra, C.L. Grzeskowiak, J. Ju, I.H. Liu, S.H. Chiou, A.A. Salahudeen, A.R. Smith, B.C. Deutsch, L. Liao, A.J. Zemek, F. Zhao, K. Karlsson, L.M. Schultz, T.J. Metzner, L.D. Nadauld, Y.Y. Tseng, S. Alkhairy, C. Oh, P. Keskula, D. Mendoza-Villanueva, F.M. De La Vega, P.L. Kunz, J.C. Liao, J.T. Leppert, J.B. Sunwoo, C. Sabatti, J.S. Boehm, W.C. Hahn, G.X.Y. Zheng, M.M. Davis, C.J., Kuo, Organoid modeling of the tumor immune microenvironment. Cell. 175(7), 1972-88 e16 (2018)","DOI":"10.1016\/j.cell.2018.11.021"},{"issue":"1","key":"1172_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41577-023-00896-4","volume":"24","author":"Z Zhou","year":"2024","unstructured":"Z. Zhou, Y. Pang, J. Ji, J. He, T. Liu, L. Ouyang, W. Zhang, X.L. Zhang, Z.G. Zhang, K. Zhang, W. Sun, Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies. Nat. Rev. Immunol. 24(1), 18\u201332 (2024)","journal-title":"Nat. Rev. Immunol."},{"key":"1172_CR19","doi-asserted-by":"crossref","unstructured":"K.K. Dijkstra, C.M. Cattaneo, F. Weeber, M. Chalabi, J. van de Haar, L.F. Fanchi, M. Slagter, D.L. van der Velden, S. Kaing, S. Kelderman, N. van Rooij, M.E. van Leerdam, A. Depla, E.F. Smit, K.J. Hartemink, R. de Groot, M.C. Wolkers, N. Sachs, P. Snaebjornsson, K. Monkhorst, J. Haanen, H. Clevers, T.N. Schumacher, E.E. Voest, Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 174(6), 1586\u201398 e12 (2018)","DOI":"10.1016\/j.cell.2018.07.009"},{"key":"1172_CR20","doi-asserted-by":"crossref","unstructured":"Z. Wang, H.P. McWilliams-Koeppen, H. Reza, J.R. Ostberg, W. Chen, X. Wang, C. Huynh, V. Vyas, W.C. Chang, R. Starr, J.R. Wagner, B. Aguilar, X. Yang, X. Wu, J. Wang, W. Chen, E. Koelker-Wolfe, C.S. Seet, A. Montel-Hagen, G.M. Crooks, S.J. Forman, C.E. Brown, 3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells. Cell. 29(4), 515\u2009\u2013\u200927 e8 (2022)","DOI":"10.1016\/j.stem.2022.02.009"},{"issue":"5","key":"1172_CR21","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.bj.2023.100633","volume":"46","author":"A Chao","year":"2023","unstructured":"A. Chao, R.C. Wu, C.Y. Lin, T.C. Chang, C.H. Lai, Small cell neuroendocrine carcinoma of the cervix: from molecular basis to therapeutic advances. Biomed. J. 46(5), 100633 (2023)","journal-title":"Biomed. J."},{"issue":"1","key":"1172_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12022-020-09660-z","volume":"32","author":"S Uccella","year":"2021","unstructured":"S. Uccella, S. La Rosa, J. Metovic, D. Marchiori, J.Y. Scoazec, M. Volante, O. Mete, M. Papotti, Genomics of High-Grade neuroendocrine neoplasms: Well-Differentiated neuroendocrine tumor with High-Grade features (G3 NET) and neuroendocrine carcinomas (NEC) of various anatomic sites. Endocr. Pathol. 32(1), 192\u2013210 (2021)","journal-title":"Endocr. Pathol."},{"issue":"1","key":"1172_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12967-022-03511-7","volume":"20","author":"V Melone","year":"2022","unstructured":"V. Melone, A. Salvati, D. Palumbo, G. Giurato, G. Nassa, F. Rizzo, L. Palo, A. Giordano, M. Incoronato, M. Vitale, C. Mian, I. Di Biase, S. Cristiano, V. Narciso, M. Cantile, A. Di Mauro, F. Tatangelo, S. Tafuto, R. Modica, C. Pivonello, M. Salvatore, A. Colao, A. Weisz, R. Tarallo, Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J. Transl Med. 20(1), 306 (2022)","journal-title":"J. Transl Med."},{"key":"1172_CR24","unstructured":"N. Cancer Genome Atlas Research, M. Albert Einstein College of, S. Analytical Biological, H. Barretos Cancer, M. Baylor College of, H. Beckman Research Institute of City of, A. Buck Institute for Research on, C. Canada's Michael Smith Genome Sciences, S. Harvard Medical, F.G.C.C. Helen, S. Research Institute at Christiana Care Health, B. HudsonAlpha Institute for, L.L.C. Ilsbio, M. Indiana University School of, V. Institute of Human, B. Institute for Systems, C. International Genomics, B. Leidos, H. Massachusetts General, U. McDonnell Genome Institute at Washington, W. Medical College of, C. Medical University of South, C. Memorial Sloan Kettering Cancer, C. Montefiore Medical, NantOmics, I. National Cancer, A.N. National Hospital, I. National Human Genome Research, S. National Institute of Environmental Health, D. National Institute on, D. Other Communication, L.H.S.C. Ontario Tumour Bank, O.I.f.C.R. Ontario Tumour Bank, T.O.H. Ontario Tumour Bank, H. Oregon, U. Science, C.-S.M.C. Samuel Oschin Comprehensive Cancer Institute, S.R.A. International, S. St Joseph's Candler Health, Eli, L.B.I.o.M.I.o.T. Edythe, U. Harvard, H. Research Institute at Nationwide Children's, U. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, B. University of, M.D.A.C.C. University of Texas, H. University of Abuja Teaching, B. University of Alabama at, I. University of California, C. University of California Santa, C. University of Kansas Medical, L. University of, C. University of New Mexico Health Sciences, H. University of North Carolina at Chapel, C. University of Oklahoma Health Sciences, P. University of, R.a.P.M.S. University of Sao Paulo, C. University of Southern, W. University of, M. University of Wisconsin School of, H. Public, I. Van Andel Research, L. Washington University in St, Integrated genomic and molecular characterization of cervical cancer. Nature. 543(7645), 378\u201384 (2017)"},{"key":"1172_CR25","doi-asserted-by":"crossref","unstructured":"L. Jiang, J. Huang, B.W. Higgs, Z. Hu, Z. Xiao, X. Yao, S. Conley, H. Zhong, Z. Liu, P. Brohawn, D. Shen, S. Wu, X. Ge, Y. Jiang, Y. Zhao, Y. Lou, C. Morehouse, W. Zhu, Y. Sebastian, M. Czapiga, V. Oganesyan, H. Fu, Y. Niu, W. Zhang, K. Streicher, D. Tice, H. Zhao, M. Zhu, L. Xu, R. Herbst, X. Su, Y. Gu, S. Li, L. Huang, J. Gu, B. Han, B. Jallal, H. Shen, Y. Yao, Genomic landscape survey identifies SRSF1 as a key oncodriver in small cell lung cancer. PLoS Genet. 12(4), e1005895 (2016)","DOI":"10.1371\/journal.pgen.1005895"},{"key":"1172_CR26","doi-asserted-by":"crossref","unstructured":"Z. Sondka, N.B. Dhir, D. Carvalho-Silva, S. Jupe, Madhumita, K. McLaren, M. Starkey, S. Ward, J. Wilding, M. Ahmed, J. Argasinska, D. Beare, M.S. Chawla, S. Duke, I. Fasanella, A.G. Neogi, S. Haller, B. Hetenyi, L. Hodges, A. Holmes, R. Lyne, T. Maurel, S. Nair, H. Pedro, A. Sangrador-Vegas, H. Schuilenburg, Z. Sheard, S.Y. Yong, J. Teague, COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 52(D1), D1210\u2013D7 (2024)","DOI":"10.1093\/nar\/gkad986"},{"issue":"6127","key":"1172_CR27","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"B. Vogelstein, N. Papadopoulos, V.E. Velculescu, S. Zhou, L.A. Jr. Diaz, K.W. Kinzler, Cancer genome landscapes. Science. 339(6127), 1546\u20131558 (2013)","journal-title":"Science"},{"issue":"7471","key":"1172_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"C. Kandoth, M.D. McLellan, F. Vandin, K. Ye, B. Niu, C. Lu, M. Xie, Q. Zhang, J.F. McMichael, M.A. Wyczalkowski, M.D.M. Leiserson, C.A. Miller, J.S. Welch, M.J. Walter, M.C. Wendl, T.J. Ley, R.K. Wilson, B.J. Raphael, L. Ding, Mutational landscape and significance across 12 major cancer types. Nature. 502(7471), 333\u2013339 (2013)","journal-title":"Nature"},{"key":"1172_CR29","doi-asserted-by":"crossref","unstructured":"T.L. Dayton, N. Alcala, L. Moonen, L. den Hartigh, V. Geurts, L. Mangiante, L. Lap, A.F.M. Dost, J. Beumer, S. Levy, R.S. van Leeuwaarde, W.M. Hackeng, K. Samsom, C. Voegele, A. Sexton-Oates, H. Begthel, J. Korving, L. Hillen, L.A.A. Brosens, S. Lantuejoul, S. Jaksani, N.F.M. Kok, K.J. Hartemink, H.M. Klomp, I.H.M. Borel Rinkes, A.M. Dingemans, G.D. Valk, M.R. Vriens, W. Buikhuisen, J. van den Berg, M. Tesselaar, J. Derks, E.J. Speel, M. Foll, L. Fernandez-Cuesta, H. Clevers, Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites. Cancer Cell. 41(12), 2083\u201399 e9 (2023)","DOI":"10.1016\/j.ccell.2023.11.007"},{"key":"1172_CR30","doi-asserted-by":"crossref","unstructured":"W. Yang, J. Soares, P. Greninger, E.J. Edelman, H. Lightfoot, S. Forbes, N. Bindal, D. Beare, J.A. Smith, I.R. Thompson, S. Ramaswamy, P.A. Futreal, D.A. Haber, M.R. Stratton, C. Benes, U. McDermott, M.J. Garnett, Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41(Database issue), D955\u201361 (2013)","DOI":"10.1093\/nar\/gks1111"},{"issue":"6522","key":"1172_CR31","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"S. Krishna, F.J. Lowery, A.R. Copeland, E. Bahadiroglu, R. Mukherjee, L. Jia, J.T. Anibal, A. Sachs, S.O. Adebola, D. Gurusamy, Z. Yu, V. Hill, J.J. Gartner, Y.F. Li, M. Parkhurst, B. Paria, P. Kvistborg, M.C. Kelly, S.L. Goff, G. Altan-Bonnet, P.F. Robbins, Rosenberg, Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 370(6522), 1328\u20131334 (2020)","journal-title":"Science"},{"issue":"18","key":"1172_CR32","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/1078-0432.CCR-21-0849","volume":"27","author":"N Levin","year":"2021","unstructured":"N. Levin, B.C. Paria, N.R. Vale, R. Yossef, F.J. Lowery, M.R. Parkhurst, Z. Yu, M. Florentin, G. Cafri, J.J. Gartner, M.L. Shindorf, L.T. Ngo, S. Ray, S.P. Kim, A.R. Copeland, P.F. Robbins, S.A. Rosenberg, Identification and validation of T-cell receptors targeting RAS hotspot mutations in human cancers for use in Cell-based immunotherapy. Clin. Cancer Res. 27(18), 5084\u20135095 (2021)","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"1172_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000342","volume":"44","author":"BC Paria","year":"2021","unstructured":"B.C. Paria, N. Levin, F.J. Lowery, A. Pasetto, D.C. Deniger, M.R. Parkhurst, R. Yossef, S.P. Kim, M. Florentin, L.T. Ngo, S. Ray, S. Krishna, P.F. Robbins, S.A. Rosenberg, Rapid identification and evaluation of Neoantigen-reactive T-Cell receptors from single cells. J. Immunother. 44(1), 1\u20138 (2021)","journal-title":"J. Immunother"},{"issue":"1","key":"1172_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/eji.202149329","volume":"52","author":"MA Eiva","year":"2022","unstructured":"M.A. Eiva, D.K. Omran, J.A. Chacon, D.J. Jr. Powell, Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. Eur. J. Immunol. 52(1), 96\u2013108 (2022)","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"1172_CR35","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"P. Voabil, M. de Bruijn, L.M. Roelofsen, S.H. Hendriks, S. Brokamp, M. van den Braber, A. Broeks, J. Sanders, P. Herzig, A. Zippelius, C.U. Blank, K.J. Hartemink, K. Monkhorst, J. Haanen, T.N. Schumacher, D.S. Thommen, An ex vivo tumor fragment platform to dissect response to PD-1 Blockade in cancer. Nat. Med. 27(7), 1250\u20131261 (2021)","journal-title":"Nat. Med."},{"issue":"7870","key":"1172_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"G. Oliveira, K. Stromhaug, S. Klaeger, T. Kula, D.T. Frederick, P.M. Le, J. Forman, T. Huang, S. Li, W. Zhang, Q. Xu, N. Cieri, K.R. Clauser, S.A. Shukla, D. Neuberg, S. Justesen, G. MacBeath, S.A. Carr, E.F. Fritsch, N. Hacohen, M. Sade-Feldman, K.J. Livak, G.M. Boland, P.A. Ott, D.B. Keskin, C.J. Wu, Phenotype, specificity and avidity of antitumour CD8(+) T cells in melanoma. Nature. 596(7870), 119\u2013125 (2021)","journal-title":"Nature"},{"issue":"7870","key":"1172_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"J.X. Caushi, J. Zhang, Z. Ji, A. Vaghasia, B. Zhang, E.H. Hsiue, B.J. Mog, W. Hou, S. Justesen, R. Blosser, A. Tam, V. Anagnostou, T.R. Cottrell, H. Guo, H.Y. Chan, D. Singh, S. Thapa, A.G. Dykema, P. Burman, B. Choudhury, L. Aparicio, L.S. Cheung, M. Lanis, Z. Belcaid, M. El Asmar, P.B. Illei, R. Wang, J. Meyers, K. Schuebel, A. Gupta, A. Skaist, S. Wheelan, J. Naidoo, K.A. Marrone, M. Brock, J. Ha, E.L. Bush, B.J. Park, M. Bott, D.R. Jones, J.E. Reuss, V.E. Velculescu, J.E. Chaft, K.W. Kinzler, S. Zhou, B. Vogelstein, J.M. Taube, M.D. Hellmann, J.R. Brahmer, T. Merghoub, P.M. Forde, S. Yegnasubramanian, H. Ji, D.M. Pardoll, K.N. Smith, Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 596(7870), 126\u2013132 (2021)","journal-title":"Nature"},{"issue":"6583","key":"1172_CR38","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"F.J. Lowery, S. Krishna, R. Yossef, N.B. Parikh, P.D. Chatani, N. Zacharakis, M.R. Parkhurst, N. Levin, S. Sindiri, A. Sachs, K.J. Hitscherich, Z. Yu, N.R. Vale, Y.C. Lu, Z. Zheng, L. Jia, J.J. Gartner, V.K. Hill, A.R. Copeland, S.K. Nah, R.V. Masi, B. Gasmi, S. Kivitz, B.C. Paria, M. Florentin, S.P. Kim, K.I. Hanada, Y.F. Li, L.T. Ngo, S. Ray, M.L. Shindorf, S.T. Levi, R. Shepherd, C. Toy, A.Y. Parikh, T.D. Prickett, M.C. Kelly, R. Beyer, S.L. Goff, J.C. Yang, P.F. Robbins, S.A. Rosenberg, Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 375(6583), 877\u2013884 (2022)","journal-title":"Science"},{"key":"1172_CR39","doi-asserted-by":"crossref","unstructured":"J. Chiffelle, D. Barras, R. Petremand, A. Orcurto, S. Bobisse, M. Arnaud, A. Auger, B.N. Rodrigo, E. Ghisoni, C. Sauvage, D. Saugy, A. Michel, B. Murgues, N. Fahr, M. Imbimbo, M. Ochoa de Olza, S. Latifyan, I. Crespo, F. Benedetti, R. Genolet, L. Queiroz, J. Schmidt, K. Homicsko, S. Zimmermann, O. Michielin, M. Bassani-Sternberg, L.E. Kandalaft, U. Dafni, J. Corria-Osorio, L. Trueb, D. Dangaj Laniti, A. Harari, G. Coukos, Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity. (2024)","DOI":"10.1101\/2023.07.21.544585"},{"key":"1172_CR40","doi-asserted-by":"crossref","unstructured":"K. Kawasaki, K. Toshimitsu, M. Matano, M. Fujita, M. Fujii, K. Togasaki, T. Ebisudani, M. Shimokawa, A. Takano, S. Takahashi, Y. Ohta, K. Nanki, R. Igarashi, K. Ishimaru, H. Ishida, Y. Sukawa, S. Sugimoto, Y. Saito, K. Maejima, S. Sasagawa, H. Lee, H.G. Kim, K. Ha, J. Hamamoto, K. Fukunaga, A. Maekawa, M. Tanabe, S. Ishihara, Y. Hamamoto, H. Yasuda, S. Sekine, A. Kudo, Y. Kitagawa, T. Kanai, H. Nakagawa, T. Sato, An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping. Cell. 183(5), 1420\u201335 e21 (2020)","DOI":"10.1016\/j.cell.2020.10.023"},{"issue":"2","key":"1172_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1470-2045(12)70570-3","volume":"14","author":"N Keat","year":"2013","unstructured":"N. Keat, K. Law, M. Seymour, J. Welch, T. Trimble, D. Lascombe, A. Negrouk, International rare cancers initiative. Lancet Oncol. 14(2), 109\u2013110 (2013)","journal-title":"Lancet Oncol."},{"issue":"11","key":"1172_CR42","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"P. Horak, C. Heining, S. Kreutzfeldt, B. Hutter, A. Mock, J. Hullein, M. Frohlich, S. Uhrig, A. Jahn, A. Rump, L. Gieldon, L. Mohrmann, D. Hanf, V. Teleanu, C.E. Heilig, D.B. Lipka, M. Allgauer, L. Ruhnke, A. Lassmann, V. Endris, O. Neumann, R. Penzel, K. Beck, D. Richter, U. Winter, S. Wolf, K. Pfutze, C. Georg, B. Meissburger, I. Buchhalter, M. Augustin, W.E. Aulitzky, P. Hohenberger, M. Kroiss, P. Schirmacher, R.F. Schlenk, U. Keilholz, F. Klauschen, G. Folprecht, S. Bauer, J.T. Siveke, C.H. Brandts, T. Kindler, M. Boerries, A.L. Illert, N. von Bubnoff, P.J. Jost, K. Spiekermann, M. Bitzer, K. Schulze-Osthoff, C. von Kalle, B. Klink, B. Brors, A. Stenzinger, E. Schrock, D. Hubschmann, W. Weichert, H. Glimm, S. Frohling, Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 11(11), 2780\u20132795 (2021)","journal-title":"Cancer Discov"},{"issue":"9 Suppl 3","key":"1172_CR43","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1097\/IGC.0000000000000262","volume":"24","author":"T Satoh","year":"2014","unstructured":"T. Satoh, Y. Takei, I. Treilleux, M. Devouassoux-Shisheboran, J. Ledermann, A.N. Viswanathan, S. Mahner, D.M. Provencher, L. Mileshkin, E. Avall-Lundqvist, P. Pautier, N.S. Reed, K. Fujiwara, Gynecologic Cancer Intergroup (GCIG) consensus review for small cell carcinoma of the cervix. Int. J. Gynecol. Cancer. 24(9 Suppl 3), S102\u2013S108 (2014)","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"1172_CR44","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ygyno.2011.04.011","volume":"122","author":"GJ Gardner","year":"2011","unstructured":"G.J. Gardner, D. Reidy-Lagunes, P.A. Gehrig, Neuroendocrine tumors of the gynecologic tract: A society of gynecologic oncology (SGO) clinical document. Gynecol. Oncol. 122(1), 190\u2013198 (2011)","journal-title":"Gynecol. Oncol."},{"key":"1172_CR45","unstructured":"FDA newsroom, DA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. U.S. FOOD, & DRUG ADMINISTRATION. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs Accessd 10 April 2025"},{"key":"1172_CR46","unstructured":"NIH Office of Communication, NIH establishes nation\u2019s first dedicated organoid development center to reduce reliance on animal modeling. National Institutes of Health. https:\/\/www.nih.gov\/news-events\/news-releases\/nih-establishes-nations-first-dedicated-organoid-development-center-reduce-reliance-animal-modeling?sessionid= Accessed 25 September 2025"},{"key":"1172_CR47","doi-asserted-by":"crossref","unstructured":"N.J. Dwarshuis, K. Parratt, A. Santiago-Miranda, K. Roy, Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies. Adv. Drug Deliv Rev. 114222\u2013114239 (2017)","DOI":"10.1016\/j.addr.2017.06.005"},{"issue":"3","key":"1172_CR48","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1002\/cam4.5095","volume":"12","author":"H Feng","year":"2023","unstructured":"H. Feng, L. Qiu, Z. Shi, Y. Sheng, P. Zhao, D. Zhou, F. Li, H. Yu, Y. You, H. Wang, M. Li, S. Zhu, Y. Du, J. Cui, J. Sun, Y. Liu, H. Jiang, X. Wu, Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy. Cancer Med. 12(3), 3313\u20133327 (2023)","journal-title":"Cancer Med."},{"issue":"4","key":"1172_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"B. Langmead, S.L. Salzberg, Fast gapped-read alignment with Bowtie 2. Nat. Methods. 9(4), 357\u2013359 (2012)","journal-title":"Nat. Methods"},{"issue":"9","key":"1172_CR50","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, M.A. DePristo, The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20(9), 1297\u20131303 (2010)","journal-title":"Genome Res."},{"issue":"8","key":"1172_CR51","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"S. Kim, K. Scheffler, A.L. Halpern, M.A. Bekritsky, E. Noh, M. Kallberg, X. Chen, Y. Kim, D. Beyter, P. Krusche, C.T. Saunders, Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods. 15(8), 591\u2013594 (2018)","journal-title":"Nat. Methods"},{"key":"1172_CR52","doi-asserted-by":"crossref","unstructured":"E. Talevich, A.H. Shain, T. Botton, B.C. Bastian, CNVkit: Genome-Wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12(4), e1004873 (2016)","DOI":"10.1371\/journal.pcbi.1004873"},{"issue":"1","key":"1172_CR53","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1186\/s12859-020-03919-2","volume":"21","author":"S Gillis","year":"2020","unstructured":"S. Gillis, A. Roth, PyClone-VI: scalable inference of clonal population structures using whole genome data. BMC Bioinform. 21(1), 571 (2020)","journal-title":"BMC Bioinform."},{"key":"1172_CR54","unstructured":"S.M.A. Islam, M. Diaz-Gay, Y. Wu, M. Barnes, R. Vangara, E.N. Bergstrom, Y. He, M. Vella, J. Wang, J.W. Teague, P. Clapham, S. Moody, S. Senkin, Y.R. Li, L. Riva, T. Zhang, A.J. Gruber, C.D. Steele, B. Otlu, A. Khandekar, A. Abbasi, L. Humphreys, N. Syulyukina, S.W. Brady, B.S. Alexandrov, N. Pillay, J. Zhang, D.J. Adams, I. Martincorena, D.C. Wedge, M.T. Landi, P. Brennan, M.R. Stratton, S.G. Rozen, L.B. Alexandrov, Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. Cell Genom. 2(11), None (2022)"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01172-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01172-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01172-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:47:26Z","timestamp":1771926446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01172-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01172-y","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was conducted following the Declaration of Helsinki, the International Ethical Guidelines for Health-related Research Involving Humans of Council for International Organizations of Medical Sciences, and the Approach to the Ethical Review of Biomedical Research Involving Humans (2016) of Ministry of Health of the People\u2019s Republic of China. All human samples were obtained with the participants\u2019 informed consent and approved by the IRB of the Ethics Committee of Shanghai Chest Hospital (Ethics number: KS(Y)2078) and Obstetrics & Gynecology Hospital of Fudan University (Ethics number: 2018-77-X1). This study involves a single-center, single-arm Phase I clinical trial assessing the efficacy of Autologous Tumor-Infiltrating Lymphocyte Infusion (GT201) for the treatment of metastatic recurrent advanced solid tumors. The trial is registered on ClinicalTrials.gov (identifier NCT05430360) by Grit Biotechnology on June 24, 2022 (First Posted).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All mouse experiments were approved by the Institutional Animal Care and Use Committee of Laboratory Animal Center, School of Life Sciences, Fudan University (2020JS038) and conducted in accordance with its guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal experiment"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}